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Abstract: All newborn screening (NBS) for mucopolysaccharidosis-I (MPS-I) is carried out by the
measurement of α-iduronidase (IDUA) enzymatic activity in dried blood spots (DBS). The majority of
low enzyme results are due to pseudodeficiencies, and studies from the Mayo Clinic have shown that
the false positive rate can be greatly reduced by including a second-tier analysis of glycosaminoglycans
(GAGs) in DBS as part of NBS. In the present study, we obtained newborn DBS from 13 patients with
severe MPS-I and 2 with attenuated phenotypes. These samples were submitted to four different
GAG mass spectrometry analyses in a comparative study: (1) internal disaccharide; (2) endogenous
disaccharide; (3) Sensi-Pro; (4) Sensi-Pro Lite (a variation of Sensi-Pro with a simplified workflow).
Patients with attenuated MPS-I show less GAG elevation than those with severe disease, and all MPS-I
patients were separated from the reference range using all four methods. The minimal differential
factor (lowest GAG marker level in MPS-I samples divided by highest level in the reference range of
30 random newborns) was about two for internal disaccharide, Sensi-Pro, and Sensi-Pro Lite methods.
The endogenous disaccharide was clearly the best method with a minimal differential of 16-fold.
This study supports use of second-tier GAG analysis of newborn DBS, especially the endogenous
disaccharide method, as part of NBS to reduce the false positive rate.
Keywords: newborn screening; glycosaminoglycans; mucopolysaccharidosis; hurler syndrome;
scheie syndrome; mass spectrometry; biochemical genetics
1. Introduction
Worldwide newborn screening (NBS) of MPS-I (OMIM Entry #607014) is done exclusively by the
first-tier measurement of α-iduronidase enzymatic activity (IDUA, EC 3.2.1.76) in dried blood spots
(DBS), either by tandem mass spectrometry (MS/MS) or by digital microfluidics fluorometry [1,2].
The rate of below cutoff samples is about 20 per 100,000 newborns using MS/MS [1]. Many of the
hits from MS/MS- and fluorometry-based enzyme analysis are false positives, because of the partial
overlap of the reference and affected ranges [3] and because of the presence of pseudodeficiencies [4].
This is the typical situation with NBS for lysosomal storage diseases. It would be prudent to develop a
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second-tier test that could identify most of the false positives as part of NBS so as to minimize the
number of follow-up cases and anxiety to families. As an example, MS/MS measurement of psychosine
in DBS greatly reduces the number of false positives in NBS of Krabbe disease, as well as helping
to stratify patients into early versus late-onset disease [5]. Biochemical measurement of psychosine
is too time-consuming to be used for first-tier NBS, and it appears to be more powerful than DNA
sequencing for prognosis [5].
IDUA is a lysosomal enzyme that is required for breakdown of the glycosaminoglycans (GAGs)
heparan sulfate and dermatan sulfate in lysosomes, and there are numerous studies showing that these
polymers are elevated in plasma and urine from MPS-I patients (shown later). GAG analysis in DBS is
currently not used for first-tier NBS of MPS-I because the analysis time per sample is still too long, and
the false positive rate is well above that seen with IDUA measurement [6,7]. However, there is a place
for GAG measurement in DBS as part of NBS. Recent data shows that this measurement is a powerful
tool for reducing false positives when carried out as a second stage NBS test after measurement of
IDUA activity [8].
In the current study, we report data on the levels of GAG-derived biomarkers in newborn DBS
from MPS-I patients using four different MS/MS approaches.
2. Methods
Studies with DBS were approved by the Univ. of Washington IRB board (numbrer 5580, approved
7/1/2020). Staff at the National MPS Society used their registry to reach out to families with MPS-I
patients for consent to participate in the study. In appropriate states, family members used published
protocols to request a stored newborn DBS from their state NBS laboratory. De-identified information
about the affected patient and the DBS was sent to the Gelb laboratory. Clinical information and
genotype (when available) for all patients is provided as Table S1. The state-specific DBS storage
conditions are also provided.
GAG analyses were carried out using standard operating procedures provided as
Supplementary Material.
3. Results
3.1. GAG-Derived Biomarkers and Methods of Detection
Iduronic acid is found in heparan sulfate and dermatan sulfate (also known as chondroitin sulfate
B) GAG polymers. In MPS-I, deficiency of IDUA leads to accumulation of these polymers. By far,
the most common approach to quantify these GAGs in DBS involves enzymatic degradation with
bacterial lyases; heparinases for heparan sulfate and chondroitinase B for dermatan sulfate (Figure 1).
Samples are treated with a mixture of three bacterial heparan sulfate lysases (heparinases I, II, and III
from Flavobacterium heparinum). Each isoform has a specific preference for structural elements in the
heparan sulfate chain, and the use of all three presumably results in more complete digestion of the GAG
polymer to form disaccharides. Most of the previous studies measure the amounts of disaccharides that
contain an unsaturated uronic acid as part of the heparinase- or chondroitinase-released disaccharide
(Figure 1). Figure 1 also gives the names of the relevant disaccharides based on the conventions
published previously [9]. Some laboratories use other abbreviated names, and a correspondence table
is given as Table S2. We refer to this commonly used approach as the internal disaccharide method.
Each GAG polymer yields many such disaccharide fragments as the GAG is a repeat of these units.
LC-MS/MS is used to quantify the disaccharide fragments in underivatized form. Heparinase and
chondroitinase B treatment also yields a single disaccharide, each of which lacks an unsaturated sugar
(Figure 1), and this is called the non-reducing end because it is on the opposite end of the GAG chain
from the end that is attached to the protein core of the proteoglycan (reducing end). The non-reducing
end fragment is not analyzed in the internal disaccharide method.
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Figure 1. (A). Heparan sulfatide disaccharide repeat unit showing sulfation or acetylation on the 
amino group or sulfation on the 6-position of glucosamine. The 2-position of the iduronic acid residue 
can also be sulfated (not shown). Degradation with bacterial heparinase lyases yield internal 
disccharides containing an unsaturated uronic acid (D0A0, D0S0, right) plus the non-reducing end 
disaccharides that lacks unsaturation (I0S0, I0S6, left). (B). Dermatan sulfate (chondroitin sulfate B) 
disaccharide repeat unit showing sulfation at the 4-position of GalNAc (major disaccharide in 
dermatan sulfate). Digestion with chondroitinase B lyase generates unsaturated internal disccharides 
(D0a4) and the non-reducing end lacking unsaturation (not shown). In the internal disaccharide 
method, the disaccharides are analyzed without derivatization. With Sensi-Pro and Sensi-Pro Lite, 
the disaccharides are derived at carbon-1 of the amino-sugar with aniline/NaCNBH3 (not shown). 
Endogenous enzymes present in human tissues can also cleave GAG chains, and an endogenous 
disaccharide biomarker was reported to be elevated in urine from MPS-I patients [10]. This biomarker 
contains a uronic acid (iduronic acid or glucuronic acid) linked to N-acetyl-hexosamine (GlcNAc or 
GalNAc) and contains a single sulfate [11]. Its exact structure is unknown, and we refer to it as UA-
HNAc(1S) (presumably UA is iduronic acid rather than glucuronic acid, but this was not proven). 
Figure 1. (A). Heparan sulfatide disaccharide repeat unit showing sulfation or acetylation on the amino
group or sulfation on the 6-position of glucosamine. The 2-position of the iduronic acid residue can
also be sulfated (not shown). Degradation with bacterial heparinase lyases yield internal disccharides
containing an unsaturated uronic acid (D0A0, D0S0, right) plus the non-reducing end disaccharides that
lacks unsaturation (I0S0, I0S6, left). (B). Dermatan sulfate (chondroitin sulfate B) disaccharide repeat
unit showing sulfation at the 4-position of GalNAc (major disaccharide in dermatan sulfate). Digestion
with chondroitinase B lyase generates unsaturated internal disccharides (D0a4) and the non-reducing
end lacking unsaturation (not shown). In the internal disaccharide method, the disaccharides are
analyzed without derivatization. With Sensi-Pro and Sensi-Pro Lite, the disaccharides are derived at
carbon-1 of the amino-sugar with aniline/NaCNBH3 (not shown).
Endogenous enzym s pres nt in human tissues can also cleave GAG chains, and an endogenous
disac haride biomarker was reported to be elevated in urine from MPS-I patients [10]. This biomarker
contains a uronic acid (iduronic acid or glucuronic acid) linked to N-acetyl-hexosamine (GlcNAc or
GalNAc) and contains a single sulfate [11]. Its exact structure is unknown, and we refer to it as
UA-HNAc(1S) (presumably UA is iduronic acid rather than glucuronic acid, but this was not proven).
The endogenous enzyme(s) are hydrolases rather than lyases, as the biomarker lacks an unsaturated
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uronic acid. The biomarker presumably comes from the non-reducing end of the GAG polymer, but it
could also be an internal disaccharide that is liberated by a double enzymatic cleavage of the chain.
The third method is Sensi-Pro [12]. It involves a combination of protease digestion, degradation of
GAG polymers with heparinases (Figure 1), and derivatization of the reducing ends of the disaccharides.
Both the internal disaccharides and non-reducing disaccharide can be quantified in the same LC-MS/MS
analysis, but Sensi-Pro makes use of the non-reducing end only.
The GAG analysis methods as well as a modification of Sensi-Pro developed in the current study
(Sensi-Pro Lite) are summarized in Table 1. The internal disaccharide method does not involve a
derivatization step. Without derivatization, the analytes are highly polar and are analyzed using
hydrophilic-interaction HPLC columns (HILIC-type). Internal standards used are structural analogs
of the biomarkers (i.e., chondrosine). A disadvantage of this is that the internal standard does not
accurately account for suppression of ionization of the analytes by matrix components since the internal
standard and analyte do not co-elute during LC. Additionally, the MS/MS response factors for analytes
and internal standard are different. See Discussion for a more complete analysis of this problem.
In cases where the internal standard and analyte are not chemically identical, we report apparent
analyte levels defined in Supplementary Material.
Table 1. Comparison of four glycosaminoglycans (GAG)-analysis methods.
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In the endogenous disaccharide method, the analytes are derivatized with 1-phenyl-
3-methyl-5-pyrazolone (PMP). This adds a hydrophobic element to the structures so that LC can
be carried out with conventional reverse-phase columns. Internal standards are not currently
available for this method, and the structural analog chondroitin disaccharide di-4S (Carbosynth,
Inc., Berkshire, UK) was used (efforts are underway in the Gelb laboratory to determine the precise
structure of the marker and to prepare an internal standard). Sensi-Pro involves derivatization with
aniline/NaCNBH3. This hydrophobic tagging permits use of reverse-phase LC columns. Another
reason for use of aniline derivatization is that it allows for the preparation of a chemically-identical,
but isotopically-distinguished, internal standard. This is prepared by derivatization of chemically
synthesized non-reducing end disaccharide with deuterium labeled aniline [12].
3.2. Results Using the Internal Disaccharide Method
Several papers using this method have been published by Tomatsu and co-workers
(for example, [13]), and our initial studies were carried out using the protocol reported by this laboratory.
After incubation of the DBS punch in buffer with heparinases, the sample is submitted to ultra-filtration
using a 96-well filter plate. We explored an alternative method of quenching the enzymatic digest
with methanol to precipitate proteins followed by centrifugation to remove insolubles. As a first step,
we showed that the internal disaccharides D0A0, D0S0, and D0a4 as well as chondrosine internal
standard are soluble in 80% methanol. Solutions of authentic disaccharides in water (10–500 pmole
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in 50 µL) were treated with 200 µL methanol or with 200 µL water. After centrifugation (15 min at
3000× g), the supernatant was analyzed by LC-MS/MS. No differences were observed in the water
versus methanol mixtures (not shown), thus, showing that all the disaccharides remain soluble in
80% methanol.
A set of three MPS-I patient DBS samples and a healthy DBS control were used to compare
the filtration and methanol quenching methods side-by-side. After incubation of DBS punches with
heparinases and chondroitinase B, a fraction of the mixture was removed (20 µL) and to this was
added 80 µL of methanol. After centrifugation, the supernatant was removed and analyzed by
LC-MS/MS. The remaining enzyme reaction mixture (~120 µL) was filtered through the filter plate
and processed for LC-MSMS. Results indicate that the two methods yield equivalent results. Levels of
D0A0, D0S0, and D0a4 markers were equally elevated in MPS-I samples compared to healthy DBS
controls (not shown).
The bacterial heparinases are known to be Ca2+ dependent [14,15]. Enzymatic activity was
completely abolished if EDTA was added to the buffer to remove enzyme-bound Ca2+. However, in the
absence of chelating agent and added Ca2+, heparinase activity was about 50% of that measured after
Ca2+ supplementation. Altogether, the data suggest that routine laboratory buffers contain sufficient
Ca2+ as a contaminant in buffer reagents and water to support partial activity of the heparinases. In all
previous reports of GAG-derived disaccharides reported by Tomatsu et al., heparinase digest buffer
was not supplemented with Ca2+ (for example, [13]). We carried out a comparison study using the
internal disaccharide method using buffer with and without added Ca2+. The results in Figure S1 show
similar disaccharide levels indicating that Ca2+ addition is not necessarily essential. Nevertheless, in all
subsequent studies we added Ca2+ to the heparinase digestion buffer to avoid possible fluctuation
in results from variation in the amount of contaminating Ca2+ in non-supplemented buffers. Some
laboratories also add dithiothreitol to the digestion buffer (personal communication with D. Matern,
Mayo Clinic, Rochester, MN, USA), and we included this reductant in our buffer to minimize the
chance of oxidative damage to the lyases.
Figure 2 shows the levels of internal disaccharides derived from heparan sulfate (D0A0 and D0S0)
and dermatan sulfate (D0a4) in newborn DBS from 13 severe MPS-I patients, 2 attenuated MPS-I
patients, and 30 random newborns (presumably non-MPS-I). Apparent pmol of biomarker per DBS
punch were obtained using chondrosine as an internal standard.
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Figure 2. Levels of heparan sulfate-derived (D0A0, D0S0) and dermatan sulfate-derived (D0a4) internal
disaccharides measured in dried blood spots (DBS) from newborn mucopolysaccharidosis-I (MPS-I)
patients using the internal disaccharide method with heparinase digestion in buffer with Ca2+ and
dithiothreitol. As a result of the limited sample, DBS from attenuated MPS-I patients were processed
only in buffer without Ca2+ and dithiothreitol; however, data in Figure S1 suggest that GAG biomarker
levels would not change significantly if Ca2+ and DTT were used. Note that a single random newb rn
gave high D0A0 and 0S levels. This same sample showed high D0A0 and D0S0 levels in the Sensi-Pro
Lite analysis (Figure 7). Asterisked dots are from newborn DBS that were stored at ambient t mperature,
ll others wer stored frozen.
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3.3. Results Using the Endogenous Disaccharide Method
As a first step toward establishing the endogenous disaccharide method [10] in our laboratory,
we measured the MPS-I marker UA-HNAc(1S) as its PMP derivative in urine samples from all types of
MPS patients (MPS-I, -II, -IIIA, -IIIB, -IIIC, -IIID, -IVA, -IVB, -VI, and VII) and found relatively high levels
only in MPS-I urine (Table S3, consistent with the previous report [10]). We also studied fibroblasts
from most types of MPS patients and found high level MPS-I marker only in MPS-I cells (Table S3).
These results show the exquisite specificity of UA-HNAc(1S) for MPS-I as reported previously [10,11].
We then analyzed the MPS-I endogenous GAG marker in newborn DBS samples. Figure 3 shows
typical LC-MS/MS chromatograms using two 3 mm punches using a newborn DBS from a severe
MPS-I patient, an attenuated MPS-I patient, and two random newborns. Well defined multiple reaction
monitoring (MRM) peaks were seen for the two MPS-I samples, but the signal for the two non-MPS-I
samples was essentially noise-level. Figure 4 shows the level of the UA-HNAc(1S) marker as its
PMP derivative measured using two 3 mm DBS punches from 30 random newborns (presumably
non-MPS-I), from 13 newborns with severe MPS-I, and from two newborns with attenuated MPS-I.
Apparent fmole per two 3 mm DBS punches is given based on use of PMP-derivatized chondroitin
disaccharide di-4S as an internal standard.
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Figure 4. Levels of endogenous disaccharide biomarker UA-HNAc(1S) PMP derivative in newborn DBS
from 30 random newborns (non-MPS-I), from 13 newborns with severe MPS-I, and from 2 newborns
with attenuated MPS-I. Asterisked dots are from newborn DBS that were stored at ambient temperature,
all others were stored frozen.
In the same LC-MS/MS runs used to measure the MPS-I marker, we also included MRM channels
for the other endogenous markers for each MPS sub-type (except MPS-VI, since we could not detect the
MPS-VI endogenous biomarker in urine and fibroblasts from confirmed MPS-VI patients). Figure S2
shows the levels of MPS-IIIA, -IIIB, -IIIC, -IIID, -IVA, -IVB, and -VII biomarkers using newborn DBS
from 30 random newborns, 13 severe MPS-I patients and two attenuated MPS-I patients. In all
cases, the level of biomarkers in the MPS-I samples overlapped with the reference range (non-MPS-I
samples) or slight elevations were seen for a subset of the MPS-I samples. As expected these additional
biomarkers are overall not useful for detection of MPS-I patients.
The exception was the endogenous biomarker for MPS-II. The MPS-II biomarker is designated
UA-HNAc(1S)-late retention time, since it is isobaric with the MPS-I marker but elutes later in the
LC run. Results are shown in Figure 5. Levels of this marker in newborn MPS-I DBS were above
the reference range (30 random newborns) for most of the severe MPS-I samples. Three of 13 severe
MPS-I DBS and both attenuated MPS-I DBS showed levels overlapping with the reference range.
The elevation seen with some of the severe MPS-I DBS were comparable to the levels seen in newborn
DBS from three MPS-II patients (Figure 5). The MPS-I newborn DBS showing the lowest amount of
the MPS-II marker was one of the three samples stored at ambient temperature rather than frozen
(Figure 5), suggesting that this marker is not stable without freezing. The MPS-II endogenous marker
provides some diagnostic power for MPS-I, but is clearly not as reliable as the MPS-I biomarker
(compare Figures 4 and 5).
The endogenous disaccharide method uses a very large excess of PMP reagent to derivatize the
biomarkers. When PMP is detected using a dedicated MRM channel, it is fount that it is fully eluted
from the LC column before 3 min, and the 0–3 min region is diverted to waste rather than to the MS/MS
ionization source. Thus, there is no concern with use of PMP.
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Figure 5. Levels of endogenous disaccharide biomarker UA-HNAc(1S) (late retention time) PMP
derivative in newborn DBS from 30 random newborns (non-MPS-I), from 13 severe MPS-I patients,
from two attenuated MPS-I patients, and from three MPS-II patients. Asterisked dots are from newborn
DBS that were stored at ambient temperature, all others were stored frozen.
3.4. Results with Sensi-Pro
The original Sensi-Pro method is a multi-step process [12]. The sample is first treated with the
non-specific protease Pronase to digest the protein core of the proteoglycans. The highly anionic GAG
polysaccharides are captured on an anion exchange resin, which is washed to elute non-bound material
followed by washing with high salt buffer to elute the GAG chains. The latter are then desalted by
passage through a column of size-exclusion gel. The GAG-containing fraction is concentrated to
dryness then digest d overnigh with heparinases and dri d again. The original Sen i-Pro method uses
ammonium acetate buffer for heparinase diges io , which is foll wed by acylation of buffer ammonia
using propionic anhydride [12]. We replaced the mmonium acetate buffer with HEPES to avoid the
acylat on step. The next step was derivatization in ace ic acid/dimethylsulfoxide mixed solvent with
anilin in the re ence of NaCNBH3. This leads to attachment of aniline to carbon-1 of the reducing
end of all GAG- eriv d fragments including the non-reducing end the internal disaccharides.
After solvent removal, the residue was taken up in solvent for injection onto LC-MS/MS.
We meas red the level of the two Sens -Pro ma kers I0S0 and I0S6 (Figure 1) in newborn DBS
samples using internal st ndards that con ai ed six deuteriums in the aniline tag (thus, chemi ally
identical to the analytes). As shown in Figure S3, the sig al for I0S6 was quite noisy, and it was difficult
to obtain an accurat integ al of the I0S6 peak. We obtained obtain mor accurat values of I0S6 by
using the MRM ch nel for I0S0. I0S0 nd I0S6 have different LC retention tim s, and some of the I0S6
und rgoes ch mical cleavage to lose the sulfate group in the heated electrospray ionization source
and, thus, appears in the MRM channel for I0S0 giving peaks, which can be accurately integrated
(Figur S4).
Figure 6 shows th level of Sensi-Pro biomarkers in newborn DBS from 13 severe MPS-I pa ient ,
two attenuated MPS-I patients, and 30 random newborns. The levels of internal dis haride markers
(D0A0 and D0S0) measured in the same LC-MS/M run (these along with the on-r ducing end
fragments are p oduced by enzymatic digestion of GAGs) are also s own. Valu s f r all samples are
provided in Table S4.
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3.5. Results with Sensi-Pro Lite
Given the complexity of the Sensi-Pro analysis compared to the other GAG-analysis methods,
we explored a highly simplified method. e omitted the protease, ion exchange, and desalting steps.
The DBS punch was first incubated in buffer with bacterial hepara\nases, as was done for the internal
disaccharide method. The sample was concentrated to dryness and dissolved and submitted to
derivatization with aniline/NaCNBH3 in acetic acid/dimethylsulfoxide.
Figure 7 shows the levels of Sensi-Pro Lite biomarkers in newborn DBS from 13 severe MPS-I
patients, two attenuated MPS-I patients, and 30 random newborns. The levels of internal disaccharide
markers (D0A0 and D0S0) measured in the same LC-MS/MS run are also shown. Values for all samples
are provided in Table S3.
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DBS from newborns in particular since these samples are most relevant for the use of GAG analysis as
a component of NBS, and there is very little data with newborn samples. Obtaining newborn DBS from
MPS-I patients is difficult, as it requires locating families with an affected patient in states where the
stored samples are still available. Over the past ~2 years and with major help from the National MPS
Society, we have been able to obtain newborn MPS-I DBS including two from patients with attenuated
disease. The inclusion of attenuated patients is especially important, because there is almost no prior
data on GAG levels in newborn DBS from these patients. We are continuing to obtain as many samples
as possible, and the current report is based on the samples we have obtained during the past ~2 years.
The NBS community is justifiably unsettled about using GAG analysis as a go/no-go NBS criterion
to follow first-tier measurement of IDUA enzymatic activity in DBS. There is a general sense that
attenuated MPS-I patients respond very well to early treatment and should be identified as part of NBS.
The present study is limited to mass spectrometry-based GAG analysis, which is generally
accepted to be far s perior to the measurement of bulk levels of intact GAG polymers in urine b
assays that rely on binding of cationic fluoro etric dyes. Furthermore, only mass spectrometry assays
can be applied to DBS a thus be incorporated into NBS. This is an important consideration given that
the majority of at-risk newborns identified only by low IDUA activity in DBS are false positives, due i
part to common pseudodeficiencies [8], and there is the obvious desire to reduce anxiety to families by
minimizing the NBS follow-up referrals that may take weeks to collect and analyze diagnostic data.
Mass spectrometric analysis of intact GAG polymers is problematic because of the enormous
number of molecular species due to chemical variation of disaccharide units in the polymer chain.
Thus, all methods are based on detection of biomarkers that are short GAG fragments generated either
via enzymatic or non-enzymatic depoly erization or f rmed endogenously in tissues. The most
common et o is to degra e the GAG polymer with bacterial hydrolases and lyases, and this is the
basis of the internal disaccharide etho described in this paper. A variation of this method is to
non-enzy atically degrade the GAG polymer by partial methanolysis to generate methyl glycosi es of
disacch rides [16]. We did not study this metho in the current study, since we had limited newborn
DBS samples, nd it is expect d to give results similar to the internal disaccharid method using
bacterial degradation enzymes. We also studied three methods that look at the non-reducing end of
the GAG chain, namely Sensi-Pro and its variation Sensi-Pro Lite, and the endogenous is cc ri
et , the most recent of the published ethods.
With the internal disaccharide method, the heparan sulfate-derived GAG markers D0A0 and
D0S0 show elev tion in all MPS-I DBS tested above the reference rang (Figure 2). The levels in DBS
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from the two attenuated MPS-I patients were lower than those in the majority of the samples from
severe MPS-I patients. For the dermatan sulfate-derived marker D0a4, there was overlap in levels in
the attenuated MPS-I samples with those in the reference range. Looking at the lowest level in patients
and the highest level in non-patients, the fold difference (referred to as the “minimum differential” is
2.4-fold for D0A0, 3.0-fold for D0S0, and 1.5-fold for D0a4 for severe MPS-I patients. The minimum
differentials for the attenuated MPS-I patients are 1.4-fold for D0A0, 0.9-fold for D0S0 (i.e., overlap
with the reference range), and 0.7-fold for D0a4. Note that an outlier was seen for one of the random
newborn DBS (presumably normal), which exhibited high D0A0 and D0S0 levels in both the internal
disaccharide method (Figure 2) and Sensi-Pro Lite (Figure 7) is not included in these calculations of
minimum differential. We suspect that the high levels of biomarkers in this random newborn may
be indicative of a previously undetected enzyme deficiency, but we have no additional data about
this newborn.
These results are similar to results reported previously for GAG biomarker levels in newborn DBS
from MPS-I patients. Wijburg and colleagues reported data on newborn DBS from 10 MPS-I patients,
including a single Scheie patient (attenuated MPS-I). The latter showed the lowest level of elevation;
the minimal differential was 1.8-fold for D0A0 and ~2.7 for D0a4 (de Ruijter et al., 2012). Tomatsu and
colleagues reported a minimal differential of ~1.7-fold for D0A0 and ~1.5-fold for D0S0 for a dataset
of newborn DBS with three MPS-I patients and 30 non-patients; the severity of the MPS-I was not
provided (Tomatsu et al., 2010). Similar trends were reported in a second study from Tomatsu and
co-workers on three additional MPS-I patients [17]. Recently, the Mayo Clinic reported a large scale
study of GAG biomarkers in DBS from MPS-I screen positive newborns [8]. A total of 1166 newborn
DBS were analyzed. Among these, 13 showed the largest elevation of D0A0 (3- to 9-fold higher than
the top of the reference range) along with elevation of D0a4 (8- to 50-fold higher than the top of
the reference range). The clinical status of these patients is not known; however, the genotype was
available and showed 10/13 with two pathogenic mutations, two with pathogenic/likely pathogenic,
and one with pathogenic/VUS). Nine of the 1166 newborns showed a lower degree of GAG biomarker
elevation, up to 2-fold and 4-fold above the top of the reference range for D0A0 and D0a4, respectively.
Genotyping showed 6/9 with at least one pseudodeficiation variation, 3/9 with pseudodeficiency/VUS,
and 1 with pathogenic/likely pathogenic.
The endogenous disaccharide method shows the highest disease-to-non-disease discrimination
among the four methods tested in this study with a minimum differential of 12.4-fold (Figure 3). This is
due to the observation that the biomarker is essentially undetectable in non-MPS-I newborn DBS. This
is not the case for the internal disaccharide method where clear LC-MSMS MRM peaks were seen for
all 30 non-MPS-I newborn DBS. The endogenous disaccharide method also shows clear separation
between the severe and attenuated MPS-I newborn DBS (although only two attenuated samples were
available for this study). An additional advantage of the endogenous disaccharide method is that no
enzymatic or chemical digestion is needed and thus the pre-LC-MS/MS sample preparation time is
shorted. The disadvantage is that the relatively low level of marker in MPS-I patient samples requires
use of a mass spectrometry with high-end sensitivity. For this study, the endogenous markers were
measured with a Sciex 6500 triple quadrupole mass spectrometer (using one or two 3 mm DBS punches).
However, some investigation was done using a Waters Xevo TQ-S instrument, and this provided
marker detection with similar signal-to-noise although two 3 mm DBS are needed (not shown).
Despite the fact that Sensi-Pro measures the level of GAG non-reducing end, the MPS-I/non-MPS-I
discriminatory power of this method is similar to that of the internal disaccharide method using I0S0
(compare Figures 2 and 6). The I0S6 marker showed very poor discrimination (Figure 6). Sensi-Pro
Lite performed slightly better than Sensi-Pro for the I0S0 marker, and performed much better than
Sensi-Pro for the I0S6 marker (compare Figures 6 and 7). Again, a key advantage of the endogenous
disaccharide method is the virtual absence of biomarker MS/MS signal for non-MPS-I DBS.
Only for Sensi-Pro and Sensi-Pro Lite were we able to use a chemically-identical,
isotopically-distinguished internal standard (I0S0 and I0S6 derivatized with deuterated aniline).
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The other two methods make use of the structural analogs chondrosine and chondroitin disaccharide
di-4S as the internal standards. Thus, for these two methods, the moles of biomarker reported are
apparent values that different from the true values by a constant, the value of which is unknown (due to
differential mass spectrometer response factors for analyte and internal standard). Many laboratories
calibrate their GAG analysis methods by using commercially available GAG polymers or disaccharide
standards made by enzymatic digestion of GAG polymers. However, these materials are not available as
certified reagents where the absolute abundance of material is accurately determined. These materials
are likely not pure by weight, and thus reliable measurement of moles by gravimetric methods is not
possible (see Gelb, 2018 for a detailed discussion of this issue) [18]. In the case of the methanolysis
method, chemically identical, isotopically labeled internal standards are made available by degradation
of the GAG polymer using deuterated methanol [16] but again the absolute amount of GAG polymer is
not known a priori, nor is the absolute moles of internal standard known after methanolysis. These are
very important issues that are usually not considered in GAG analysis in biochemical genetics
laboratories, and they make it virtually impossible to compare reported absolute GAG abundance
levels between different reference laboratories. This implies that each reference laboratory will have to
determine their own disease-specific reference ranges, which is not very practical given the difficulty
in obtaining newborn DBS from MPS-I patients, especially from those with attenuated disease. Work is
in progress in the author’s laboratory to make available a certified internal standard for use in the
endogenous disaccharide method.
All of the newborn DBS were stored frozen in the state NBS lab except for three stored at ambient
temperature (indicated by asterisks in Figure 2 and Figures 4–7). The data shows a slight tendency
of MPS-I marker instability for ambient-stored DBS, but there is insufficient data to make a firm
conclusion. Loss of the MPS-II marker with ambient temperature storage may be a bigger factor
(Figure 5).
The present study is focused on MPS-I, which is the highest priority given that NBS for this disease
has started in several NBS laboratories. The study is being continued using DBS from newborns with
other forms of MPS disease and results will be presented when available.
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